Thu, September 6, 2012
Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012

Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable B


//health-fitness.news-articles.net/content/2012/ .. inaclotide-for-the-treatment-of-irritable-b.html
Published in Health and Fitness on Thursday, August 30th 2012 at 12:47 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) and [ Forest Laboratories, Inc. ] (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESSa" at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 26759985. To access the webcast, please visit the Investors section of Ironwoodas website at [ www.ironwoodpharma.com ] or the Forest website at [ www.frx.com ] at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting August 30, 2012 at approximately 5:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on September 6, 2012. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 26759985. The archived webcast will be available on Ironwoodas website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. LINZESS (linaclotide), Ironwoodas guanylate cyclase-C (GC-C) agonist, is an FDA-approved drug for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit [ www.ironwoodpharma.com ].

About Forest Laboratories, Inc.

Forest Laboratoriesa (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory, gastrointestinal, and pain management medicine. The Companyas pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit [ www.FRX.com ].


Publication Contributing Sources